FDA Comes Under Fire From Sen. Clinton Over Plan B Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York Democrat seeks a Senate Health Committee oversight hearing and General Accounting Office investigation as part of full review of FDA’s rejection of OTC status for the emergency contraceptive.
You may also be interested in...
Plan B GAO Investigation Sought By House Members
Group led by Rep. Waxman is requesting that GAO examine communications between the White House and HHS regarding FDA's decision not to approve the Plan B emergency contraceptive switch application.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.